Abstract

Our review of retapamulin (DTB 2008; 46: 76–9) described a trial that compared retapamulin and oral cefalexin in people with infected dermatoses.1 In doing so, we incorrectly stated that the study was underpowered with regards to the number of patients included in its per-protocol analysis. This error does not affect our article's Conclusion.